Physician profile
John Burnett
NPI 1932151420
$712.90
in general payments reported to CMS, 2019-2025
20 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2022: $30.79 · 2024: $60.31 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $97.23 | 2024-2025 | |
| Astellas Pharma US INC | $83.05 | 2019 | |
| Eisai INC. | $59.17 | 2022-2025 | |
| Genentech USA, INC. | $56.70 | 2025 | Venclexta, Itovebi |
| Lilly USA, LLC | $50.30 | 2019-2025 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $48.16 | 2025 | Iclusig, Fruzaqla |
| Janssen Biotech, INC. | $36.17 | 2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $34.46 | 2019-2024 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $29.45 | 2019 | |
| Tesaro, INC. | $25.75 | 2019 | |
| Daiichi Sankyo INC. | $25.39 | 2025 | Injectafer |
| Incyte Corporation | $23.63 | 2025 | Niktimvo, Jakafi |
| Dendreon Pharmaceuticals LLC | $20.83 | 2025 | Provenge |
| Celgene Corporation | $20.57 | 2019 | |
| Genmab U.S., INC. | $19.79 | 2025 | Epkinly |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $18.62 | 2025 | Qinlock |
| Syndax Pharmaceuticals, INC. | $18.29 | 2025 | |
| Puma Biotechnology, INC. | $16.57 | 2025 | |
| Servier Pharmaceuticals LLC | $15.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.